D-0702-2017 Class III Terminated
FDA drug recall D-0702-2017 was initiated by Sun Pharmaceutical Industries, Inc. on Mar 22, 2017 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities). The recall status is terminated (terminated Jul 11, 2018). Affected quantity: 14,784 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- May 17, 2017
- Initiation Date
- Mar 22, 2017
- Termination Date
- Jul 11, 2018
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 14,784 bottles
Product description
Olanzapine Tablets, 20 mg, packaged in a) 30-count bottles (NDC 62756-556-83), b) 100-count bottles (NDC 62756-556-88), and c) 1000-count bottles (NDC 62756-556-18), Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, 350 Gujarat, India.
Reason for recall
Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities).
Distribution pattern
Nationwide in the USA and Puerto Rico
Code information
Lot #: a) JKR5759A, Exp 04/18; b) JKP0943A, Exp 04/17, JKR5520A, Exp 04/18; c) JKP0988A, Exp 04/17
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0702-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026